116 related articles for article (PubMed ID: 16938579)
1. New translocations in a case of atypical B-cell chronic lymphocytic leukemia: involvement of ATM, MLL, and TP53 genes.
Collado R; Hueso J; Cabello AI; Oliver I; Egea M; Orero M; Miguel-Sosa A; Cigudosa JC; Benítez J; Barragán E; Carbonell F
Cancer Genet Cytogenet; 2006 Sep; 169(2):176-8. PubMed ID: 16938579
[No Abstract] [Full Text] [Related]
2. Imperfect correlation between p53 dysfunction and deletion of TP53 and ATM in chronic lymphocytic leukaemia.
Carter A; Lin K; Sherrington PD; Atherton M; Pearson K; Douglas A; Burford A; Brito-Babapulle V; Matutes E; Catovsky D; Pettitt AR
Leukemia; 2006 Apr; 20(4):737-40. PubMed ID: 16437137
[No Abstract] [Full Text] [Related]
3. A novel functional assay using etoposide plus nutlin-3a detects and distinguishes between ATM and TP53 mutations in CLL.
Best OG; Gardiner AC; Majid A; Walewska R; Austen B; Skowronska A; Ibbotson R; Stankovic T; Dyer MJ; Oscier DG
Leukemia; 2008 Jul; 22(7):1456-9. PubMed ID: 18200038
[No Abstract] [Full Text] [Related]
4. [Gene atm and chronic lymphocytic leukemia - review].
Zhu DX; Xu W; Li JY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2008 Oct; 16(5):1242-6. PubMed ID: 18928637
[TBL] [Abstract][Full Text] [Related]
5. No evidence for DNA methylation of the ATM promoter CpG island in chronic lymphocytic leukemia.
Mikeska T; Carney DA; Seymour JF; Dobrovic A
Leuk Lymphoma; 2012 Jul; 53(7):1420-2. PubMed ID: 22204453
[No Abstract] [Full Text] [Related]
6. ATM modulates the loading of recombination proteins onto a chromosomal translocation breakpoint hotspot.
Sun J; Oma Y; Harata M; Kono K; Shima H; Kinomura A; Ikura T; Suzuki H; Mizutani S; Kanaar R; Tashiro S
PLoS One; 2010 Oct; 5(10):e13554. PubMed ID: 21048951
[TBL] [Abstract][Full Text] [Related]
7. Missense mutation and defective function of ATM in a childhood acute leukemia patient with MLL gene rearrangement.
Oguchi K; Takagi M; Tsuchida R; Taya Y; Ito E; Isoyama K; Ishii E; Zannini L; Delia D; Mizutani S
Blood; 2003 May; 101(9):3622-7. PubMed ID: 12511424
[TBL] [Abstract][Full Text] [Related]
8. Ataxia telangiectasia mutated-deficient B-cell chronic lymphocytic leukemia occurs in pregerminal center cells and results in defective damage response and unrepaired chromosome damage.
Stankovic T; Stewart GS; Fegan C; Biggs P; Last J; Byrd PJ; Keenan RD; Moss PA; Taylor AM
Blood; 2002 Jan; 99(1):300-9. PubMed ID: 11756185
[TBL] [Abstract][Full Text] [Related]
9. ATM and chronic lymphocytic leukemia: mutations, and not only deletions, matter.
Rossi D; Gaidano G
Haematologica; 2012 Jan; 97(1):5-8. PubMed ID: 22210328
[No Abstract] [Full Text] [Related]
10. Ataxia telangiectasia mutated-dependent regulation of topoisomerase II alpha expression and sensitivity to topoisomerase II inhibitor.
Tamaichi H; Sato M; Porter AC; Shimizu T; Mizutani S; Takagi M
Cancer Sci; 2013 Feb; 104(2):178-84. PubMed ID: 23163762
[TBL] [Abstract][Full Text] [Related]
11. Biallelic ATM inactivation significantly reduces survival in patients treated on the United Kingdom Leukemia Research Fund Chronic Lymphocytic Leukemia 4 trial.
Skowronska A; Parker A; Ahmed G; Oldreive C; Davis Z; Richards S; Dyer M; Matutes E; Gonzalez D; Taylor AM; Moss P; Thomas P; Oscier D; Stankovic T
J Clin Oncol; 2012 Dec; 30(36):4524-32. PubMed ID: 23091097
[TBL] [Abstract][Full Text] [Related]
12. Splenic infarction associated with rapidly progressive chronic lymphocytic leukemia with complex karyotype and ATM mutation.
Dyer MJ; Majid A; Walewska R; Gesk S; Harder L; Siebert R; Morgan B
Leuk Res; 2011 May; 35(5):e55-7. PubMed ID: 21185599
[No Abstract] [Full Text] [Related]
13. The potential anticancer agent PK11195 induces apoptosis irrespective of p53 and ATM status in chronic lymphocytic leukemia cells.
Santidrián AF; Cosialls AM; Coll-Mulet L; Iglesias-Serret D; de Frias M; González-Gironès DM; Campàs C; Domingo A; Pons G; Gil J
Haematologica; 2007 Dec; 92(12):1631-8. PubMed ID: 18055986
[TBL] [Abstract][Full Text] [Related]
14. Mutations in the ATM gene lead to impaired overall and treatment-free survival that is independent of IGVH mutation status in patients with B-CLL.
Austen B; Powell JE; Alvi A; Edwards I; Hooper L; Starczynski J; Taylor AM; Fegan C; Moss P; Stankovic T
Blood; 2005 Nov; 106(9):3175-82. PubMed ID: 16014569
[TBL] [Abstract][Full Text] [Related]
15. ATM gene alterations in chronic lymphocytic leukemia patients induce a distinct gene expression profile and predict disease progression.
Guarini A; Marinelli M; Tavolaro S; Bellacchio E; Magliozzi M; Chiaretti S; De Propris MS; Peragine N; Santangelo S; Paoloni F; Nanni M; Del Giudice I; Mauro FR; Torrente I; Foà R
Haematologica; 2012 Jan; 97(1):47-55. PubMed ID: 21993670
[TBL] [Abstract][Full Text] [Related]
16. ATM germline heterozygosity does not play a role in chronic lymphocytic leukemia initiation but influences rapid disease progression through loss of the remaining ATM allele.
Skowronska A; Austen B; Powell JE; Weston V; Oscier DG; Dyer MJ; Matutes E; Pratt G; Fegan C; Moss P; Taylor MA; Stankovic T
Haematologica; 2012 Jan; 97(1):142-6. PubMed ID: 21933854
[TBL] [Abstract][Full Text] [Related]
17. Microarray analysis reveals that TP53- and ATM-mutant B-CLLs share a defect in activating proapoptotic responses after DNA damage but are distinguished by major differences in activating prosurvival responses.
Stankovic T; Hubank M; Cronin D; Stewart GS; Fletcher D; Bignell CR; Alvi AJ; Austen B; Weston VJ; Fegan C; Byrd PJ; Moss PA; Taylor AM
Blood; 2004 Jan; 103(1):291-300. PubMed ID: 12958068
[TBL] [Abstract][Full Text] [Related]
18. Variations of the ataxia telangiectasia mutated gene in patients with chronic lymphocytic leukemia lack substantial impact on progression-free survival and overall survival: a Cancer and Leukemia Group B study.
Lozanski G; Ruppert AS; Heerema NA; Lozanski A; Lucas DM; Gordon A; Gribben JG; Morrison VA; Rai KM; Marcucci G; Larson RA; Byrd JC
Leuk Lymphoma; 2012 Sep; 53(9):1743-8. PubMed ID: 22369572
[TBL] [Abstract][Full Text] [Related]
19. Prognostic significance of ATM and TP53 deletions in Chinese patients with chronic lymphocytic leukemia.
Xu W; Li JY; Wu YJ; Yu H; Shen QD; Li L; Fan L; Qiu HX
Leuk Res; 2008 Jul; 32(7):1071-7. PubMed ID: 18035414
[TBL] [Abstract][Full Text] [Related]
20. Chronic lymphocytic leukemia and treatment resistance in cancer: the role of the p53 pathway.
Zenz T; Benner A; Döhner H; Stilgenbauer S
Cell Cycle; 2008 Dec; 7(24):3810-4. PubMed ID: 19098429
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
